Click Here For
WiredPatrol Site
"You Are a Child of the Universe, No Less than the Trees or the Stars"

In October 2008 Pfizer pays $60M settlement for consumer fraud, off label promotion....

April 15 2009 at 12:26 PM

Response to 2005 in Holland, Pfizer found guilty...

Pfizer finalizes $60M settlement with states over Off-Label Marketing of COX-2 Inhibitors

[Oct 23, 2008]   Pfizer on Wednesday said it will pay $60 million to 33 states and Washington, D.C., to settle lawsuits that claimed the company promoted the COX-2 inhibitors Bextra and Celebrex for unapproved uses, the Miami Herald reports.

The agreement is part of an $894 million settlement that the company announced last week to cover more than 90% of pending lawsuits involving the drugs.

The settlement also includes $745 million to settle personal injury claims and $89 million for consumer fraud claims brought by insurers and consumers seeking to recoup money spent on the drugs.

COX-2 inhibitors drew increased scrutiny when Merck in 2004 withdrew its COX-2 inhibitor Vioxx from the market because of a link to cardiovascular risks. Celebrex is the only remaining COX-2 inhibitor on the market.

Pfizer, as part of the settlement, will not admit to unlawful marketing practices.

However, the company will be required to submit all future television advertisement to FDA for approval, according to the New Jersey attorney general's office. Pfizer said the practice already is company policy.

Amy Schulman, senior vice president and general counsel of Pfizer, in a statement said, "As we announced last week, these settlements avoid the disruption and expense of litigation and put these matters behind us," adding, "This medicine (Bextra) was rigorously studied and tested by the company and independent medical experts, and information about its benefits and risks was fully disclosed to the FDA."

Pfizer also has agreed to other compliance measures related to its marketing practices.

New Jersey Attorney General Anne Milgram (D) in a statement said the settlement restricts companies' practices, including "ghost writing" articles and studies related to their pharmaceutical products, misrepresenting scientific data when they market the medications to physicians, and using incentives to encourage physicians to prescribe the drugs for off-label uses.

She added, "This case should send a strong message to the industry at large that New Jersey does not tolerate deception and misleading claims in the promotion of prescription drugs" (Miami Herald, 10/22).

This message has been edited by SSRIAdmin on Apr 15, 2009 12:30 PM

 Respond to this message   

  1. In July 2008, in Australia, Pfizer found Guilty of bringing discredit to the industry - admin on Apr 15, 2009, 12:35 PM
    1. So much for the standards of the Accreditation huh? n/t - admin on Apr 15, 2009, 12:37 PM

Visit RxISK ORG from Data Based Medicine
'the first free website (not sponsored by big pharma or advertising) for patients
and their doctors to research, and more importantly, easily report drug side effects'.